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Church RH, Ali I, Tate M, Lavin D, Krishnakumar A, Kok
HM, Hombrebueno JR, Dunne PD, Bingham V, Goldschmeding
R, Martin F, Brazil DP. Gremlin1 plays a key role in kidney
development and renal fibrosis. Am J Physiol Renal Physiol 312:
F1141–F1157, 2017. First published January 18, 2017; doi:10.1152/
ajprenal.00344.2016.—Gremlin1 (Grem1), an antagonist of bone
morphogenetic proteins, plays a key role in embryogenesis. A highly
specific temporospatial gradient of Grem1 and bone morphogenetic
protein signaling is critical to normal lung, kidney, and limb devel-
opment. Grem1 levels are increased in renal fibrotic conditions,
including acute kidney injury, diabetic nephropathy, chronic allograft
nephropathy, and immune glomerulonephritis. We demonstrate that a
small number of grem1/ whole body knockout mice on a mixed
genetic background (8%) are viable, with a single, enlarged left
kidney and grossly normal histology. The grem1/ mice displayed
mild renal dysfunction at 4 wk, which recovered by 16 wk. Tubular
epithelial cell-specific targeted deletion of Grem1 (TEC-grem1-cKO)
mice displayed a milder response in the acute injury and recovery
phases of the folic acid model. Increases in indexes of kidney damage
were smaller in TEC-grem1-cKO than wild-type mice. In the recovery
phase of the folic acid model, associated with renal fibrosis, TEC-
grem1-cKO mice displayed reduced histological damage and an
attenuated fibrotic gene response compared with wild-type controls.
Together, these data demonstrate that Grem1 expression in the tubular
epithelial compartment plays a significant role in the fibrotic response
to renal injury in vivo.
Gremlin; kidney; renal fibrosis; development
GREMLIN1 (Grem1) is a member of the secreted, cysteine knot
DAN family of bone morphogenetic protein (BMP) antago-
nists. Grem1 is involved in regulating a number of cell func-
tions in developing and adult tissues. A highly specific tempo-
rospatial gradient of Grem1 and BMP signaling, which is
essential for normal limb, kidney, and lung development,
occurs during embryogenesis (1, 13, 19, 20).
Grem1 homozygous knockout (KO) mice on a C57BL/6
background are neonatal lethal due to development abnormal-
ities, including bilateral agenesis of the kidneys, lung defects,
and limb malformations (1, 13, 20). Grem1 inhibition of
BMP-4 in the metanephric mesenchyme is required to facilitate
ureteric bud outgrowth and epithelial branching morphogenesis
(19). The lack of kidney development in grem1/ mice can be
rescued by deletion of one allele of BMP-4, suggesting that an
inappropriate “volume” of BMP signaling in the absence of
Grem1 leads to renal agenesis (19). Recently, it has been shown
that grem1/ mice can survive when generated on a mixed
genetic background (C57BL/6;FVB). Surviving grem1/ mice
on this background are smaller, with decreased body weight and
a shortened femoral length (1).
Several novel roles for Grem1 have recently been reported,
expanding our understanding of the diversity of Grem1 signal-
ing. Grem1 has been suggested to be proangiogenic via acti-
vation of vascular endothelial growth factor receptor 2
(VEGFR2) (21). This effect is proposed to occur via Grem1
interactions with heparin sulfate proteoglycans on the surface
of endothelial cells (4). Engagement of v3-integrins and
formation of v3-integrin-VEGFR2 complexes have also
been shown to be involved in Grem1-mediated angiogenesis
(27). Grem1 has also been shown to signal in a range of cancer
cell lines in a BMP- and VEGFR2-independent manner (14).
Grem1 levels are increased in fibrosis of the kidney, liver,
and lung and in colon cancer, pituitary adenoma, and meso-
thelioma (11, 15, 24, 30, 33). Grem1 levels are increased in
diabetic nephropathy (DN), chronic allograft nephropathy, im-
mune glomerulonephritis, and acute kidney injury (AKI) (2, 9,
17, 18, 33). Higher levels of Grem1 expression in the kidney
correlate with indexes of renal damage (8, 33). In the context
of renal fibrosis, tubular epithelial overexpression of Grem1 in
mouse models of AKI and DN resulted in increased renal
damage and a more severe phenotype (9, 17). Consistently,
Grem1 targeting has shown potential benefits, with both allelic
depletion and siRNA targeting of Grem1 protecting against the
early sequelae of DN (28, 35). Prophylactic and therapeutic
treatment with a Grem1-neutralizing antibody in a murine
model of pulmonary arterial hypertension potentiated BMP
signaling and reduced pulmonary vascular remodeling and
hypertrophy (5).
Since Grem1 expression is increased in renal tubular epithe-
lial cells in damaged human and mouse kidney, we were
interested in the specific role of Grem1 in the tubular epithe-
lium in renal injury models. The effect of whole body and
tubule epithelial cell-specific deletion of Grem1 in normal and
disease states was analyzed. Our results show that Grem1 is
required for normal kidney development and that reductions in
Grem1, specifically in the tubular epithelium, provide some
protection against AKI.
* I. Ali and M. Tate contributed equally to this work.
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MATERIALS AND METHODS
All animal experiments were approved in advance by the Queen’s
University Animal Welfare and Ethical Review Body and carried out
according to the Animal Research Reporting of In Vivo Experiments
(ARRIVE) guidelines and the principles of the 3 Rs (replacement,
refinement, or reduction of use of animals in research).
Generation of whole body Grem1 KO mice. Whole body
grem1/LacZ mice with one allele of grem1 replaced by a LacZ
cassette were provided by Prof. Richard Harland (University of
California, Berkeley, CA). The method of Canalis et al. (1) was used
to backcross these mice by a single mating to a wild-type FVB strain
to generate grem1/LacZ on a mixed C57BL/6J;FVB genetic back-
ground. These mice were crossed to yield mice lacking both copies of
the grem1 allele (grem1LacZ/LacZ or grem1/) at the expected Men-
delian frequency of 25%. Mice with two intact alleles of grem1
(grem1/) were used as wild-type controls.
Generation of tubular epithelial cell-specific Grem1 conditional
knockout (TEC-grem1-cKO) mice. The ksp-cadherin-Cre transgenic
mice on a C57BL/6J background (stock no. 012237, Jackson Labo-
ratories) express Cre recombinase under the control of the mouse
cadherin 16 (Cdh16 or Ksp1.3) promoter (29). The grem1/fl mice
on a C57BL/6 background (a generous gift from Prof. Daniel Graf,
University of Alberta, Edmonton, AB, Canada) were inbred to
generate mice with both copies of the grem1 allele flanked by loxP
recombination sequences (grem1fl/fl). The grem1/LacZ mice were
crossed with ksp-cadherin-Cre mice to generate grem1/LacZ;ksp-
cad-Cre/ offspring. These mice were then crossed with grem1fl/fl
mice to generate TEC-grem1-cKO tubule-specific deletion
(grem1LacZ/;ksp-cad-Cre/) mice, where the  allele indicates
Cre recombinase-mediated deletion of loxP-flanked grem1 alleles.
These mice were generated at the expected Mendelian frequency of
25%.
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Fig. 1. Gremlin1 (Grem1)-deficient (grem1/)
mice are smaller and have deformed limbs. A
and B: mouse tissues were analyzed using
PCR-RT and specific TaqMan probes for
Grem1 or Grem2; 18S and -actin were used as
housekeeping controls. Values (means  SE,
n  8) are shown as relative gene expression
[2Ct (gene  housekeeping gene average)].
C: grem1/ mice are smaller than wild-type
(grem/) littermates. D: grem1/ mice dis-
play limb deformities, as indicated and previ-
ously described (13). E: growth curves for 4- to
16-wk-old wild-type and grem1/ mice. F and
G: grem1/ mice have a significantly lower
body weight than wild-type littermates at 4 wk
(n 8) and 16 wk (n 5). Values are means
SE. **P 	 0.01, ***P 	 0.001 (by Student’s
unpaired t-test).
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Genotyping. Genotyping was performed using genomic DNA iso-
lated from ear biopsies and conventional PCR analysis. Specific
oligonucleotides were used to identify the following alleles in whole
body grem1/ mice: grem1 [5=-AAAGGTTCCCAAGGAGCCAT-
TCC-3= (forward) and 5=-AACAGAAGCGGTTGATGATAGTGC-3=
(reverse)] and LacZ [5=-GGTCAATCCGCCGTTTGTTCC-3= (forward)
and 5=-TAGTCACGCAACTCGCCGCACA-3= reverse)]. The following
oligonucleotides were used to identify TEC-grem1-cKO mice: grem1
[5=-AAAGGTTCCCAAGGAGCCATTCC-3= (forward) and 5=-AA-
CAGAAGCGGTTGATGATAGTGC-3= (reverse)], LacZ [5=-GGT-
CAATCCGCCGTTTGTTCC-3= (forward) and 5=-TAGTCACG-
CAACTCGCCGCACA-3= (reverse)], loxP [5=-TGGCAGAAAGAA-
TGATACCAGAA-3= (forward) and 5=-ACAGGTCACACAGT-
GAATTTGCC-3= (reverse)], and ksp-cadherin-Cre [5=-GCAGAT-
CTGGCTCTCCAAAG-3= (forward) and 5=-AGGCAAATTTTGGT-
GTACGG-3= (reverse)]. To confirm Cre/loxP-mediated deletion of
grem1, genomic DNA was isolated from kidney poles postmortem
and analyzed using the following oligonucleotides: 5=-TGGCA-
GAAAGAATGATACCAG-3= (forward) and 5=-AACAGGCTAG-
TATCAGTTACAGC-3= (reverse). The presence of a 400-bp PCR
product confirmed the Cre recombinase-mediated deletion of the
grem1 exon 2 fragment containing the entire grem1 coding sequence.
Immunohistochemistry. Paraffin-embedded kidney sections (5 
m)
from wild-type and grem1/ mice were incubated with a Col4a1
antibody (Cell Signaling Technology) according to the manufacturer’s
instructions. Col4a1-positive cells were visualized using a FITC-
labeled anti-rabbit antibody, and fluorescence intensity was captured
using ImageJ software.
In situ hybridization. The RNAscope 2.0 HD detection kit (Ad-
vanced Cell Diagnostics, Hayward, CA) was used to perform chro-
mogenic in situ hybridization of Grem1 on formalin-fixed paraffin-
embedded mouse colon sections. Briefly, paraffin-embedded colon
sections were cut at 4 
m, air-dried overnight, baked at 60°C for 1 h,
dewaxed, and air-dried before pretreatments. For all probes, a stan-
dard pretreatment protocol was employed according to the manufac-
turer’s instructions. The specifications of the Grem1 RNAscope probe
employed in this study (Mm-Grem1, catalog no. 314741) were as
follows: probe region begin, 398; probe region end, 1359. Specific
probe binding sites were detected by the RNAscope 2.0 HD detection
kit based on 3,3=-diaminobenzidine substrate, with intensity of brown
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Fig. 2. Expression of Grem1 in human tissues and primary cells. Relative levels of Grem1 and Grem2 mRNA were identified on the BioGPS platform
(www.bioGPS.org). A and B: levels of expression in a range of human tissues were measured via gene array and plotted. Tissues and cells with high levels of
Grem1 expression are indicated. MSCs, mesenchymal stem cells.
Table 1. Outcome of grem1/  grem1/ crosses
Mating Total No. of Mice grem1/ Mice grem1/ Mice grem1/ Mice grem1/ Mice That Died at P2 grem1/ Mice That Survived
grem1/  grem1/ 202 51 (25.24%) 100 (49.50%) 50 (24.75%) 46 (92%) 4 (8%)
Values represent number of offspring, with percentage of total in parentheses. P2, postnatal day 2.
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staining as a surrogate measurement of mRNA abundance. Semiquan-
titative pathology-based image analysis was carried out on tissue
sections from three wild-type and three grem1/ mice, with positive
or negative scoring recorded by three independent observers blinded
to tissue labels. All slides were then scanned using an Aperio scanner
at 40 resolution and uploaded to the Queen’s University Belfast
digital pathology suite (PathXL), where images were captured.
Induction of AKI. Female wild-type and TEC-grem1-cKO mice
were injected intraperitoneally with a single dose of vehicle (0.3 M
sodium bicarbonate) or folic acid (FA, 250 mg/kg; Sigma, Poole, UK)
on day 2 and FA (100 mg/kg in 0.2 M sodium bicarbonate) on day 14.
Blood was collected during the study by tail vein bleed and at the end
of the study by cardiac puncture.
Biochemical assays. Serum creatinine was measured using a cre-
atinine colorimetric assay kit (BioVision, Milpitas, CA), and serum
urea [blood urea nitrogen (BUN)] was measured using a QuantiChrom
Urea Assay kit (BioAssay Systems, Hayward, CA), according to the
manufacturers’ protocols.
Histology. Harvested kidneys were fixed in 10% formalin or 4%
(wt/vol) paraformaldehyde and incubated for 24 h at room tempera-
ture. Tissues were processed and embedded in paraffin wax as
previously described (28), sectioned, and placed on Superfrost glass
slides (Thermo Fisher Scientific, Poole, UK). Sections were stained
using standard histology protocols for hematoxylin and eosin and
Masson’s trichrome. Stained sections were visualized using a Nikon
Lucia cell imaging system and imaged using NIS-Elements software.
Pathology scoring. Sections were blinded and stained with periodic
acid-Schiff-diastase. Slides were rated individually on the basis of
tubular damage, inflammation, fibrosis, and casts and scored for the
degree of the parameter being measured, combined with the percent-
age of the parameter covering the whole slide. Percentage of positive
pathology was graded on a scale of 0–5 as follows: 0 (0%), 1
(0–10%), 2 (10–25%), 3 (25–50%), 4 (50–75%), 5 (75–100%).
Tubular damage was scored on the basis of tubules that were
dilated in both length and width. Inflammation was determined by
the presence of cells in the interstitial area between tubules.
Tubular casts were detected in dilated tubules by the presence of
pink staining, indicating a large amount of protein. Interstitial
fibrosis was determined by a meshed matrix between tubules that
stained pink.
Real-time PCR. RNA was extracted from kidney tissue using the
TRIreagent (Sigma-Aldrich) method. Total RNA (1 
g) was reverse-
transcribed, and TaqMan PCR was performed using specific TaqMan
probes (Roche Applied Science) for Grem1 (assay ID 314702),
collagenase type 4 1-subunit (Col4a1; assay ID 300652), vimentin
(assay ID 310719), fibronectin (assay ID 300578), and plasminogen
activator 1 (PAI-1; assay ID 310686). Analysis was carried out using
the comparative threshold (Ct) method and normalized to an
average of 18S (assay ID 307906) and -actin (assay ID 300236)
levels. Real-time PCR was carried out on a light cycler (model 480,
Roche).
Statistical analysis. Statistical analysis was carried out using
GraphPad Prism software, and graphs were generated using Prism 5.0
(GraphPad, San Diego, CA). Student’s unpaired t-test was performed
to determine significant differences between two normally distributed
groups. Student’s paired t-test was performed to determine significant
A B
Colon
C D
grem1+/+ grem1-/-
Fig. 3. Grem1 mRNA is detected in mouse
colon. RNA in situ hybridization-based gene
expression of Grem1 was detected using RNA-
scope probes and 3,3=-diaminobenzidine stain-
ing to visualize Grem1-positive cells in
grem1/ (A and C) and grem1/ (B and D)
mice. Grem1 staining was confined to the mus-
cularis mucosae and submucosal regions of the
mouse colon in the wild-type mouse. In contrast,
no signal was detected in colon sections from
grem1/ mice, as assessed by blinded assess-
ment of sections by 3 independent observers. Im-
ages, which represent findings from 4 wild-type
and 4 grem1/ mice, were captured using Aperio
slide-scanning technology at 19 (A and B) and
27 (C and D) magnification. Scale bars 30 
m.
Table 2. Kidney distribution in survivor grem1/ mice
Mouse No. Age of Cull, wk Left Kidney Right Kidney
1 4 Yes No
2 4 Yes No
3 4 Yes No
4 4 Yes No
5 4 Yes No
6 4 Yes No
7 4 Yes No
8 4 Yes No
9 16 Yes No
10 16 No Yes
11 16 Yes No
12 16 Yes Yes
13 16 Yes No
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difference when a parameter relating to the same group was compared
after a specific treatment. A one-way analysis of variance (ANOVA)
with a Bonferroni’s post hoc test was performed to compare any
differences between more than two group means. P 	 0.05 was
considered to be statistically significant.
RESULTS
Whole body grem1/ mice develop a single, enlarged
kidney. Grem1 and its homolog Grem2 [protein related to Dan
and Cerberus (PRDC)] display distinct patterns of expression
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Fig. 4. Changes in kidney size, but not structure, in
grem1/ mice. A: representative images of kidneys of
grem1/ and grem1/ mice at 16 wk. B–E: kidney
weights were recorded and plotted for grem1/ and
grem1/ mice at 4 and 16 wk or normalized to body
weight. Values are means  SE (n  5–8). ***P 	
0.001 (by Student’s unpaired t-test). F: paraffin-fixed
kidney sections were cut at 5 
m and stained using
hematoxylin and eosin (H&E), periodic acid-Schiff
(PAS), or Masson’s trichrome protocol. Scale bars 
70 
m. Stained slides were imaged on a Lucia light
microscope. Representative images from grem1/
and grem1/ mice are shown at 20 magnification.
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in mouse tissue. Using quantitative PCR, we identified the
highest levels of Grem1 mRNA in colon and lower levels in
brain (Fig. 1A). In contrast, Grem2 is highest in brain and
lower in kidney and lung (Fig. 1B). Online analysis of Grem1
expression in human tissues using the BioGPS platform (www.
bioGPS.org) confirmed that levels of Grem1 are highest in
smooth muscle, small intestine, colon, and uterus (Fig. 2A). In
addition, high levels of Grem1 were detected in human fibro-
blasts, astrocytes, endothelial cells, mesenchymal stem cells
(MSCs), and monocytes (Fig. 2A, and data not shown). Grem2
mRNA distribution was more limited, with high levels detected
in fibroblasts, liver, and breast stroma (Fig. 2B, and data not
shown). Both Grem1 and Grem2 are widely expressed in a
range of brain regions (data not shown).
Whole body deletion of grem1/ in mice on a C57BL/6
background leads to death at postnatal day 2 (P2) due to the
absence of kidneys (19, 20). Canalis and colleagues reported that
a single backcross onto an FVB background allowed some
grem1/ mice to survive into adulthood (1). We employed this
strategy and generated grem1/ mice on a mixed C57BL/6J;
FVB background. Crossing these mice led to the expected Men-
delian frequency of grem1/, grem1/, and grem1/ off-
spring (Table 1). As expected, the majority of the grem1/ mice
died at P2; only 8% survived to adulthood (Table 1). Surviving
grem1/ mice were smaller and displayed the previously de-
scribed defects in fore- and hindlimb formation (Fig. 1, C and D).
Weight at birth was lower in grem1/ than wild-type mice, and
grem1/ mice maintained a growth rate similar to that of wild
type mice up to 7–8 wk, when their body weight plateaued (Fig.
1E). At 16 wk, wild-type mice weighed 36.7  4.9 g and
grem1/ mice weighed 22.7  3.2 g (P 	 0.001; Fig. 1G).
Consistent with high levels of Grem1 detected in the colon (Fig.
1A), RNA in situ hybridization detected Grem1 in the muscularis
mucosae and submucosal regions of wild-type mouse colon, but
not in grem1/ sections (Fig. 3) (7). Gross colon histology was
normal, and grem1/ mice had elevated levels of pSmad1/5 in
colon sections, consistent with amplified BMP signaling resulting
from Grem1 deletion (data not shown). These data suggest that
Grem1 expression is maintained in the colon in the adult mouse,
where it antagonizes BMP signaling.
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Fig. 5. Reduced glomerular density, but similar
glomerular number, in grem1/ kidney. A–D:
glomeruli in grem1/ and grem1/ mouse kid-
neys were counted. Glomerular number per mm2
(density) and total glomeruli normalized to kidney
weight-to-body weight ratio (K:BW) were calcu-
lated at 4 and 16 wk. Values are means  SE (n 
5–8). ***P 	 0.001 (by Student’s unpaired t-test).
E and F: serum from grem1/ and grem1/ mice
was isolated and analyzed for serum creatinine at 4
wk (E) and 16 wk (F). Values are medians  SE
(n 4–8). *P	 0.05 (by Student’s unpaired t-test).
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Postmortem analysis revealed that grem1/ mice that died
at P2 were anephric, with no evidence of kidney development
(data not shown). In contrast, the majority of surviving
grem1/ mice developed a single, enlarged left kidney (Table
2, Fig. 4, A–E). Although the body weight of the grem1/
mice was only 60% of that of wild-type mice at 16 wk, the
left kidney of grem1/ mice was slightly larger: 213 55 mg
(wild-type) vs. 226  87 mg (grem1/) (Fig. 4D). Consis-
tently, kidney weight-to-body weight ratios for grem1/ mice
were also elevated at 4 wk, with a more pronounced difference
at 16 wk in grem1/ than wild-type mice: 5.534 0.973 g/kg
(wild-type) vs. 9.611 3.04 g/kg (grem1/) (P	 0.001; Fig.
4E). These data indicate that a minority of grem1/ mice
survive and are smaller, with an enlarged left kidney.
The single left kidney from grem1/ mice displayed
grossly normal histology, with no evidence of glomerular or
tubular defects or increased glycoprotein or collagen secretion
(Fig. 4F). Glomerular density in the single grem1/ kidney
was reduced compared with the wild-type kidney at 4 and 16
wk: 9.26 (wild-type) vs. 5.41 (grem1/) glomerulae/mm2 at 4
wk and 7.46 (wild-type) vs. 4.11 (grem1/) glomerulae/mm2
at 16 wk (Fig. 5, A and C). However, the overall number of
glomerulae was comparable between the two genotypes when
the glomerular density was normalized to kidney weight-to-
body weight ratio, suggesting that the increased size of the
single grem1/ kidney may be due to expansion of the
interstitial compartment. Serum creatinine levels were elevated
in grem1/ vs. wild-type mice at 4 wk, suggesting a mild
renal dysfunction at this time point (Fig. 5E). However, by 16
wk, serum creatinine levels had returned to normal (Fig. 5F),
suggesting a delay in the capacity of the single grem1/
kidney to cope with the filtration demands of the developing
mouse. Furthermore, RNA in situ hybridization of grem1/
and grem1/ kidneys revealed some low-level, particulate
staining (Fig. 6, A and B). Conversely, no staining was ob-
served in grem1/ kidney (Fig. 6, C and D), as expected,
enabling it to be used as a negative control.
Grem1/ mice have normal retinal vascular development
and visual responses. A novel role for Grem1 as a proangio-
genic activator of VEGFR2 has been proposed in recent years
(4, 21, 27). Based on these data, we hypothesized that
grem1/ mice may display developmental defects in vascular
development. Examination of eyes from wild-type and
grem1/ mice demonstrated that, despite a 30–40% reduc-
tion in body size of grem1/ mice (Fig. 1, E–G), eye weight
and volume were equivalent in grem1/ and wild-type mice
(Fig. 6). Gross retinal structure appeared normal, and retinal
thickness, as measured from the ganglion cell layer to the
posterior end of the outer nuclear layer (140 
m), was not
significantly different between wild-type and grem1/ mice
(data not shown). Quantitation of the number of branching
vessels within the retina showed no significant difference in
wild-type vs. grem1/ mice (Fig. 7, F–H). Consistently, there
were no significant differences in visual function of wild-type
and grem1/ mice, as assessed by electroretinogram (data not
shown).
TEC-grem1-cKO mice display milder fibrosis responses to
FA injury. We used the ksp-cadherin-Cre mouse generated
by the Igarashi laboratory to drive loxP-mediated deletion of
Grem1 in tubular epithelial cells (12). A summary of the
mating strategy used to produce TEC-grem1-cKO mice is
shown in Fig. 8A. To confirm Cre-mediated deletion of
grem1, genomic DNA was isolated from kidney poles post-
mortem and analyzed by conventional PCR. The presence of
a 400-bp PCR product confirmed the Cre recombinase-
mediated deletion of the grem1 exon 2 fragment containing
grem1+/+ grem1+/+ 
grem1-/- grem1-/- 
A B 
C D 
Kidney
Fig. 6. Grem1 mRNA expression in mouse
kidney. A–D: RNA in situ hybridization-
based gene expression of Grem1 was de-
tected using RNAscope probes and 3,3=-di-
aminobenzidine staining to visualize Grem1-
positive cells in grem1/ and grem1/
mice. Negligible signal was detected in
grem1/ mice, and no staining was ob-
served in grem1/ mice, as assessed by
blinded assessment of sections by 3 indepen-
dent observers. Images, which represent find-
ings from 4 wild-type and 4 grem1/ mice,
were captured using Aperio slide-scanning
technology at27 magnification. Scale bars
30 
m.
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the entire grem1 coding sequence (Fig. 8, B and C). Criti-
cally, Grem1 mRNA levels were significantly reduced in the
kidney of TEC-grem1-cKO mice compared with wild-type
mice, providing evidence supporting Grem1 TEC deletion
(Fig. 8D). Grem2 expression was significantly increased in
TEC-grem1-cKO mice compared with wild-type controls,
suggesting compensatory changes in these related BMP
antagonists (Fig. 8E). Interestingly, no significant difference
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was observed in BMP-4, BMP-7, or TGF1 expression in
kidneys of wild-type or TEC-grem1-cKO control mice,
suggesting that TEC deletion of Grem1 does not alter BMP
or TGF1 signaling under normal conditions (Fig. 8, F–H).
Mice were harvested 2 days after FA administration to
assess the extent of AKI. Wild-type, but not TEC-grem1-
cKO, mice displayed significant weight loss at days 1 and 2
post-FA administration (Fig. 9A). Most mice in the FA-
treated group appeared very unwell at day 2, likely due to
FA-induced acute renal failure and dehydration. Postmor-
tem, left and right kidney weight-to-body weight ratios were
significantly increased in wild-type FA-treated mice (Fig. 9,
B and C). In contrast, this increase was only significant for
the right kidney in TEC-grem1-cKO mice (Fig. 9C). Basal
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genomic DNA was isolated from kidney poles
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mice postmortem and analyzed by conven-
tional PCR. The presence of a 400-bp PCR
product confirmed the Cre recombinase-medi-
ated deletion of the grem1 exon 2 fragment
containing the entire grem1 coding sequence.
D–H: levels of Grem1, Grem2, bone morpho-
genetic protein (BMP)-4, BMP-7, and TGF1
were measured using RT-PCR with specific
TaqMan probe sets. Data were analyzed using
the Ct method and normalized to the mean
of 2 housekeeping genes (18S and -actin).
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BUN of ~20 –30 mg/dl was observed in wild-type and
TEC-grem1-cKO mice, suggesting that tubular deletion of
Grem1 does not alter basal renal filtration (Fig. 9D, day 0).
Importantly, there was no significant difference in serum
BUN levels at day 2 post-FA injection between wild-type
and TEC-grem1-cKO mice (Fig. 9D). A similar trend was
observed when serum creatinine was analyzed (data not
shown). Histological staining of kidney sections revealed
that both wild-type and TEC-grem1-cKO mice treated with
FA displayed severe kidney injury at day 2, with massive
tubular dilation and an increased presence of apoptotic cells
surrounding necrotic tubules (Fig. 9, E and F). Minimal
tubular casts and fibrosis were observed at day 2 in both
phenotypes (Fig. 9E). These data suggest that tubular dele-
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m. F and G: sections on glass microscope slides were stained with
PAS, blinded, and scored on the basis of tubular damage and inflammation as percent positive: 0 (0%), 1 (0–10%), 2 (10–25%), 3 (25–50%), 4 (50–75%), 5
(75–100%). Values are means  SE.
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tion of Grem1 in mice does not exert a protective effect in
the acute phase of FA-induced injury (Fig. 9, D–F).
Because 250 mg/kg FA was associated with a high mortality
rate, 100 mg/kg FA was used to study the effects to the day 14
end point. In response to 100 mg/kg FA, wild-type mice
displayed significantly increased serum BUN levels at day 2
that significantly decreased at day 14, indicating renal recovery
(Fig. 10A). In contrast, TEC-grem1-cKO mice exhibited a more
modest increase in serum BUN that did not reach statistical
significance (Fig. 10A). Day 14 histology revealed FA-induced
kidney damage in both groups, with the presence of some
dilated tubules and collagen and glycoprotein staining (Fig.
10B). Sections from days 2 and 14 were scored according to
severity using the parameters tubular damage, inflammation,
fibrosis, and casts and results were plotted as an overall
damage score (Fig. 10C). Consistent with previous data (Fig.
9), wild-type and TEC-grem1-cKO mice displayed similar
degrees of damage at day 2 post-FA exposure (Fig. 10C).
Interestingly, wild-type, but not TEC-grem1-cKO, mice dis-
played significantly higher kidney damage at day 14 vs. day 2,
suggesting that reduced tubular epithelial Grem1 expression
attenuates the fibrotic response to FA injury.
When RNA from kidney poles was analyzed, Grem1 levels
were significantly increased in wild-type mice, consistent
with previous data showing that Grem1 is a fibrosis-asso-
ciated gene (28, 33). This increase was abolished in TEC-
grem1-cKO mice, consistent with the ablation of grem1
alleles in the tubular epithelial cells (Fig. 11A). TGF1
expression was significantly increased at day 14 in wild-
type FA-treated, but not in TEC-grem1-cKO, mice (Fig.
11B). Consistent with an attenuated fibrosis in TEC-grem1-
cKO kidneys, the extracellular matrix genes Col4a1, fi-
bronectin, and PAI-1 were significantly increased in wild-
type FA-treated, but not TEC-grem1-cKO, mice (Fig. 11,
D–F). At day 14, vimentin levels were also higher in
wild-type kidney only (Fig. 11C). BMP-4 and BMP-7 ex-
pression levels were not significantly altered in either ge-
notype in response to FA at day 14 (Fig. 11, G and H). These
data suggest that the milder pathology of the TEC-grem1-
cKO kidney may be due to attenuated profibrotic gene
expression caused by reduced Grem1 and TGF1 signaling.
Consistently, Western blot and densitometry analysis
showed significantly increased pSmad2 and -smooth muscle
actin in wild-type FA-treated, but not TEC-grem1-cKO, mice
at day 14 (Fig. 12, A, B, D, and E). -Catenin levels were
significantly increased in both genotypes, but to a much greater
extent in wild-type kidney (Fig. 12, A–C). These data comple-
ment the gene expression data and, again, suggest that the
milder pathology of the TEC-grem1-cKO kidney may be due to
reduced Grem1 and TGF1 signaling.
We stained capillaries with Col4a1 to investigate the renal
vasculature in wild-type and TEC-grem1-cKO mice at day
14 compared with vehicle control mice (Fig. 13). Col4a1
staining detected capillaries surrounding and within the
glomeruli, as well as throughout the kidney (Fig. 13, A–D).
Wild-type FA-treated mice exhibited significantly reduced
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fluorescence intensity, indicating a reduction in the number
of blood vessels as a result of FA-induced AKI (Fig. 13, A,
B, and E). Interestingly, TEC-grem1-cKO mice did not
display significant changes in fluorescence intensity and renal
vasculature compared with TEC-grem1-cKO vehicle control mice
(Fig. 13, C–E). The data suggest that TEC-grem1-cKO mice are
protected from renal vascular loss associated with FA-induced
AKI.
DISCUSSION
Our data suggest that Grem1 contributes to kidney devel-
opment and the pathogenesis of AKI. Grem1 levels are low
in mouse kidney and highest in the colon (Fig. 1A). In
contrast, Grem2 levels are highest in mouse brain, suggest-
ing tissue-specific expression patterns for these related pro-
teins (Fig. 1B). In human cells, Grem1 levels are high in
0
20
40
60
80
100
Day 0 Day 2 Day 5 Day 10 Day 14
* *
wild-type FA
TEC-grem1-cKO FA
BU
N 
(m
g/
dL
)
A
TEC-grem1-cKO
FA
H
&
E
M
as
so
n’
s
Tr
ic
hr
om
e 
PA
S
TEC-grem1-cKO 
Veh
B wild-type
Veh
wild-type
FA
Ve
h
FA
 D
2
FA
 D
14 Ve
h
FA
 D
2
FA
 D
14
0
1
2
3
4
wild-type TEC-grem1-cKO
***
***
*
Se
ve
rit
y 
sc
or
e
C
Fig. 10. TEC-grem1-cKO mice display an attenuated renal fibrosis in FA-induced nephropathy. A: blood samples were collected from FA-injected mice at days
0, 2, 5, and 10 by tail vein bleed and at day 14 by cardiac puncture. Serum was isolated and analyzed for BUN. Values are means  SE [n  5 (wild-type) and
4 (TEC-grem1-cKO) mice]. *P 	 0.05 between groups at each time point (by Student’s unpaired t-test) and for different time points but the same genotype
(Student’s paired t-test). B: formalin-fixed kidney samples were processed and embedded in paraffin wax. Sections were cut at 4 
m and stained using H&E,
Masson’s trichrome, or PAS protocol. Scale bars  100 
m. Stained slides were imaged on a Lucia light microscope. Representative images from each group
are shown at 20 magnification. Sections on microscope glass slides were stained with PAS, blinded, and scored for tubular damage, inflammation, fibrosis, and
tubular casts. C: combined score of overall damage was plotted for wild-type and TEC-grem1-cKO vehicle (Veh), FA day 2 (FA D2), or FA day 14 (FA D14).
Slides were graded as percent positive: 0 (0%), 1 (0–10%), 2 (10–25%), 3 (25–50%), 4 (50–75%), 5 (75–100%). Values are means  SE. *P 	 0.05, ***P 	
0.001 (by 1-way ANOVA with Bonferroni’s multiple comparison test).
F1152 Grem1 IN KIDNEY DEVELOPMENT AND DISEASE
AJP-Renal Physiol • doi:10.1152/ajprenal.00344.2016 • www.ajprenal.org
fibroblasts, MSCs, and macrophages/monocytes (Fig. 2A).
Grem1 was shown to inhibit BMP2-mediated differentiation
of MSCs into osteoblasts (26). Grem1 binding to Slit pro-
teins has been demonstrated to inhibit monocyte chemotaxis
and macrophage formation (3, 22, 23). Thus, high levels of
Grem1 expression in these cells may represent a normal
homeostatic mechanism regulating MSC and monocyte
function.
The vast majority of grem1/ mice on a C57BL/6 back-
ground die shortly after birth due to renal agenesis and lung
defects, emphasizing the critical role in development (1, 10, 19,
20). Using a single backcross onto the FVB genetic back-
ground, we were able to generate grem1/ mice that survived
to adulthood (~8% of offspring from grem1/ crosses; Table
1). These grem1/ mice were smaller than wild-type controls
(Fig. 1, E–G) and also displayed the previously described fore-
and hindlimb defects (Fig. 1, C and D). The pattern of Grem1
RNA staining in the muscularis layer of the colon is consistent
with previous reports (Fig. 3) (7). The low levels of Grem1
detected in kidney epithelium are also consistent with our PCR
data (Figs. 1A and 6). The ability of a small number of
grem1/ mice to survive when the majority die is related to
the development of a single, enlarged kidney in the majority of
these mice (Fig. 4, Table 2). This larger kidney displayed
normal histology with a reduced glomerular density but an
overall glomerular number similar to wild-type mice (Fig. 5).
Why would the majority of mice develop a single, left kidney
in the absence of Grem1? Mammalian kidney development is
highly complex and involves formation of the metanephros at
embryonic day 10.5. Glial-derived neurotrophic factor then
triggers the outgrowth of the ureteric bud from the Wolffian
duct into a population of nephrogenic cells called the meta-
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Fig. 11. TEC-grem1-cKO mice are protected from increases in fibrotic gene expression in the recovery phase of FA-induced nephropathy. RNA was extracted
from kidney pole tissues from wild-type and TEC-grem1-cKO control and FA-treated mice, cDNA was generated, and quantitative PCR was performed using
specific TaqMan probes for Grem1, TGF1, vimentin, collagenase type IV 1-subunit (Col4a1), fibronectin, plasminogen activator 1 (PAI-1), BMP-4, and
BMP-7. Relative quantification was obtained using the Ct method; 18S and -actin were used as housekeeping controls. Values (means  SE) are plotted
as fold change for wild-type control (n  7), wild-type FA (n  5), TEC-grem1-cKO control (n  4), and TEC-grem1-cKO FA (n  4). Control mice were used
as the calibrator and set to 1 for each experiment. *P 	 0.05, **P 	 0.01, ***P 	 0.001 (by 1-way ANOVA with Bonferroni’s multiple comparison test).
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nephric mesenchyme (6). A range of key genes, such as WT1,
Pax2, Pax8, Foxd1, and Six2, along with signaling molecules,
such as Wnt and Ret, are involved in kidney development (6).
The development of the left kidney in the majority of
grem1/ mice may be related to the left-right asymmetry that
dominates during embryogenesis. Given the previous dogma
that Grem1 was absolutely required for kidney development,
the fact that some mice survive with a single kidney suggests
that alternate signaling molecules may be able to compensate
for the lack of Grem1. The backcross of C57BL/6 mice onto
the FVB background may increase the influence of modifier
genes that facilitate the development of a single kidney in the
absence of Grem1. The increase in Grem2 levels in the
grem1/ kidney (data not shown) suggests that Grem2 could
play a role in compensating for the loss of Grem1 during
kidney development. Further work is needed to elucidate why
the left kidney develops in the majority of these mice.
Grem1 is reported to drive angiogenesis via activation of
VEGFR2 in endothelial cells (4, 21, 27). Others have sug-
gested that Grem1 can activate VEGFR2 in renal epithelial
cells and that this pathway contributes to Grem1-induced renal
fibrosis (16). No obvious defects in retinal vascularization or
visual responses were detected in the grem1/ retina (Fig. 7,
and data not shown), suggesting that Grem1 may not play a
physiological role in retinal blood vessel formation. No other
defects in vascularization of the kidney or other tissues were
detected in grem1/ mice (data not shown). In our hands,
Grem1-mediated activation of VEGFR2 is very weak com-
pared with VEGF in endothelial colony-forming cells and even
weaker in HK-2 kidney epithelial cells (R. Church, unpub-
lished observations). Given the existing data in the literature, it
may be that Grem1-mediated activation of VEGFR2 and as-
sociated angiogenesis may only occur in pathological condi-
tions involving supraphysiological levels of Grem1.
The successful generation of TEC-grem1-cKO mice allowed
us to circumvent the challenges of the low numbers of whole
body grem1/ mice with a single kidney in our renal injury
experiments. The ksp-cadherin-Cre mouse has been used pre-
viously to facilitate renal epithelial deletion of genes, including
the insulin receptor (32). Successful development of kidneys in
these mice is likely due to the appropriate Grem1 expression
during ureteric budding, facilitating normal metanephros de-
velopment and kidney formation. Grem1 levels were signifi-
cantly lower in kidney poles from TEC-grem1-cKO than wild-
type mice (Fig. 8D), with the residual Grem1 signal likely due
to nonepithelial cells in the tissue used for RNA isolation. The
concomitant increase in Grem2 expression is interesting and
suggests that regulation of Grem1 and Grem2 may be linked to
allow compensatory changes in either protein in specific cel-
lular contexts. Although the overall damage score for TEC-
grem1-cKO mice in response to FA increased at day 14
compared with day 2 (Fig. 10C), this was not significant and
demonstrates for the first time that specific reduction of Grem1
in tubular epithelial cells attenuates the fibrotic response in
AKI. Consistently, FA-induced increases in fibrosis-associated
genes, such as vimentin, fibronectin, PAI-1, and Col4a1, were
reduced in TEC-grem1-cKO mice (Fig. 11). Importantly, TEC-
grem1-cKO FA-treated mice at day 14 did not display an
increase in TGF1 expression compared with wild-type FA-
treated mice at day 14, which showed a nearly fivefold increase
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(Fig. 11B). Protein level measurements at day 14 showed
attenuated -catenin, pSmad2, and -smooth muscle actin
expression in FA-treated TEC-grem1-cKO compared with FA-
treated wild-type mice (Fig. 12). These data suggest that
TEC-grem1-cKO mice are somewhat protected from FA-in-
duced renal fibrosis through decreased TGF1 signaling. Fur-
thermore, analysis of results from Col4a1 staining of the renal
capillaries showed that TEC-grem1-cKO mice were protected
from FA-induced damage to the vasculature, which could be an
additional mechanism of protection in response to FA injury
(Fig. 13). Previous reports demonstrated that tubular epithelial
overexpression of Grem via a kidney androgen-regulated pro-
moter aggravated renal damage in FA injury and DN after 25
wk (9, 17). The exact signaling modalities of Grem1 in the
diseased kidney are not clear. Increased Smad1/5/9 phosphor-
ylation as a measure of BMP signaling due to a genetic
reduction of Grem1 or antibody-mediated inhibition has been
reported by our group and others (5, 28). Other reports suggest
that activation of VEGFR2 and NFB inflammatory signaling
plays a role in Grem1-mediated kidney damage (16). Other
reports again imply that Grem1-mediated signaling in disease
occurs via a BMP- and VEGFR2-independent mechanism (14,
25). It is possible that a range of Grem1 signaling may be
involved in mediating its profibrotic effects in kidney and other
tissues.
Overall, these data contribute to our understanding of the
role of Grem1 in AKI, where tubular deletion of Grem1 may
have a protective effect, and complement the recent findings by
Droguett et al. (9), who showed that tubular overexpression of
Grem1 increases renal damage. In the current literature, there
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is little evidence for a role of BMPs and their antagonists in
AKI. Uterine sensitization-associated gene (USAG)-deficient
mice display attenuated renal injury and proximal tubular
damage in cisplatin-induced nephrotoxicity (34). Furthermore,
USAG-1 was found to display the highest BMP antagonist-to-
BMP ratio in two models of AKI; a lower ratio was observed
with Grem1 (31). This may also implicate USAG-1 as an
important protein in AKI. In addition to the range of studies
that support the hypothesis of targeting Grem1 in fibrotic
conditions (5, 35), these data further enhance our understand-
ing of the molecular basis of Grem1-mediated renal damage
and contribute to the body of evidence for Grem1 involvement
in renal fibrosis.
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